Figure 6

MM patient 3 profile schematic. The key signaling pathways and crosstalk relevant for MM patient 3 are presented. This profile contained multiple aberrations, including a chromosome 11:14 translocation. The profile exhibited a CUL1 deletion and increased CTNNB1; the patient was clinically resistant to bortezomib. The profile also contained an amplification of RHEB1, implicating activation of the mTOR pathway. The PI3K/mTOR inhibitor BEZ235 in combination with bortezomib was predicted to be effective in this patient.